http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TN-2010000086-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33eaca90fe66a7c52bd9c7c4cf353a58
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-731
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-431
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737
filingDate 2010-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93105a4f5ca246e85c3f3338721c4e4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_749616fe96a09d213f23930e09071d47
publicationDate 2011-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber TN-2010000086-A1
titleOfInvention Antiviral composition comprising a sulfated polysaccharide
abstract The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112220799-A
priorityDate 2007-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11966249
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426185960
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID10535
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID10535

Total number of triples: 33.